Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
10 nov. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH...
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
10 nov. 2023 07h30 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
08 nov. 2023 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
06 nov. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Priority Review of resmetirom new drug application underway in the U.S.Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023$500 million financing provides Madrigal with funds to...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
02 nov. 2023 16h05 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
28 sept. 2023 22h30 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Proposed Public Offering
28 sept. 2023 16h01 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Theratechnologies présente ses résultats financiers pour le troisième trimestre et les neuf premiers mois de l’exercice 2023 et fait le point sur ses activités commerciales
26 sept. 2023 07h30 HE
|
Theratechnologies
Revenus consolidés de 20,9 millions de dollars et BAIIA ajusté de 2,2 millions de dollars au troisième trimestre de 2023Dépôt d’une sBLA relative à la formulation F8 de la tésamoréline auprès de la...
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
26 sept. 2023 07h30 HE
|
Theratechnologies
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 millionsBLA for F8 formulation of tesamorelin submitted to FDAAgreement in principle on key amendments to loan facility with...
Theratechnologies annoncera ses résultats du troisième trimestre de l’exercice financier de 2023
18 sept. 2023 16h15 HE
|
Theratechnologies
MONTRÉAL, 18 sept. 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement...